Compare AstraZeneca plc (AZN) vs Macy's Inc (M) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AstraZeneca plc vs Macy's Inc — how do they compare? AstraZeneca plc trades at $158.64 (market cap $248.14B), while Macy's Inc trades at $23.87 (market cap $6.45B). The key difference: AstraZeneca plc is far larger — about 38.5× Macy's Inc's market cap, and Macy's Inc pays the higher dividend (3.12%). Which is the better fit depends on your goals.
| AZN | M | |
|---|---|---|
Market Cap | $248.14B | $6.45B |
Sector | Health | Consumer Cyclical |
52-Week High | $209.48 | $26.21 |
52-Week Low | $147.06 | $12.73 |
Enterprise Value | $275.41B | $10.26B |
Dividend Yield | 2.01% | 3.12% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AstraZeneca (AZN) trades at $157.39, down 2.79% amid bearish technical signals and merger speculation. The company demonstrates strong fundamentals with revenue growth to $58.74B in 2025 and a net income margin of 17.02%. Recent earnings have consistently beaten estimates, and analyst consensus is positive with 47.5% buy ratings. However, news of potential merger talks with Bristol Myers Squibb and a related legal investigation have introduced volatility.
The outlook is mixed; solid profitability and growth support long-term value, but near-term price pressure from technical indicators and merger uncertainty presents a cautious entry point. Key risks include deal execution challenges and integration complexities should a merger proceed.
Macy's stock trades at $23.78, down 4.5% over 24 hours, with technical indicators showing a bullish moving average signal but neutral oscillators. The company demonstrates improving fundamentals with three consecutive quarterly earnings beats and positive cash flow trends. Recent institutional buying and analyst coverage reflect cautious optimism amid the company's turnaround efforts.
The stock presents value investment potential with attractive valuation multiples (P/E 10.13, P/S 0.3) and improving profitability. Key risks include retail sector headwinds and execution of the 'Bold New Chapter' strategy. The consensus price target of $24.83 suggests modest upside potential from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AstraZeneca plc
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
Read more on AZN →About Macy's Inc
Founded in 1858 and based in New York City, Macy's operates 570 stores under the Macy's nameplate, 58 stores under the Bloomingdale's nameplate, and 160 freestanding Bluemercury specialty beauty stores (as of the end of fiscal-year 2021). Macy's also operates e-commerce sites and licenses two Bloomingdale's stores in the United Arab Emirates and Kuwait. Women's apparel, accessories, shoes, cosmetics, and fragrances comprised 59% of Macy's 2021 sales.
Read more on M →
